AWS
PBYI icon

Atria Wealth Solutions’s Puma Biotechnology PBYI Stock Holding History

Atria Wealth Solutions’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,200
Closed -$59.7K – 1864
2022
Q3 		$59.7K Sell
25,200
-10,000
-28% -$29.2K ﹤0.01% 1685
2022
Q2 		$100K Buy
+35,200
New +$87.5K ﹤0.01% 1531

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Atria Wealth Solutions's PBYI Position: Q4 2022 in Review

Atria Wealth Solutions sold out of Puma Biotechnology (PBYI) in Q4 2022, closing a stake of 25,200 shares — an estimated $59.7K sold.

Atria Wealth Solutions first reported a position in PBYI in Q2 2022 and held it in 2 quarters. The position peaked at $100K in Q2 2022. 88 funds tracked by Wall St. Rank hold PBYI as of Q4 2022.

  • Atria Wealth Solutions reported no remaining Puma Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Atria Wealth Solutions sold 25,200 Puma Biotechnology shares in Q4 2022, an estimated $59.7K.
  • Atria Wealth Solutions first reported a position in Puma Biotechnology in Q2 2022 and held it in 2 quarters.
  • Atria Wealth Solutions's Puma Biotechnology position peaked at $100K in Q2 2022.
  • 88 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2022.

Based on Atria Wealth Solutions's 13F filing for Q4 2022, filed 13 Feb 2023.